| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 22 | 2023 | 206 | 7.420 |
Why?
|
| Mucins | 23 | 2024 | 69 | 7.300 |
Why?
|
| Curcumin | 17 | 2020 | 115 | 6.060 |
Why?
|
| Nanoparticles | 19 | 2025 | 449 | 3.720 |
Why?
|
| Neoplasms | 28 | 2025 | 1341 | 3.240 |
Why?
|
| Antineoplastic Agents | 23 | 2025 | 979 | 2.850 |
Why?
|
| Amyotrophic Lateral Sclerosis | 4 | 2025 | 55 | 2.600 |
Why?
|
| Uterine Cervical Neoplasms | 10 | 2022 | 350 | 2.490 |
Why?
|
| Ovarian Neoplasms | 10 | 2024 | 406 | 2.440 |
Why?
|
| Benzopyrans | 7 | 2019 | 25 | 2.360 |
Why?
|
| Cell Proliferation | 29 | 2023 | 1420 | 2.250 |
Why?
|
| Cell Line, Tumor | 47 | 2023 | 2598 | 2.110 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2023 | 60 | 2.040 |
Why?
|
| Humans | 128 | 2025 | 42163 | 1.810 |
Why?
|
| Animals | 63 | 2025 | 16695 | 1.590 |
Why?
|
| Drug Carriers | 11 | 2022 | 169 | 1.580 |
Why?
|
| Colonic Neoplasms | 6 | 2023 | 223 | 1.540 |
Why?
|
| Prostatic Neoplasms | 19 | 2022 | 1068 | 1.520 |
Why?
|
| Drug Delivery Systems | 14 | 2024 | 273 | 1.520 |
Why?
|
| MicroRNAs | 12 | 2022 | 501 | 1.510 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2025 | 290 | 1.450 |
Why?
|
| Adenocarcinoma | 4 | 2022 | 287 | 1.430 |
Why?
|
| Papillomavirus Infections | 7 | 2020 | 363 | 1.410 |
Why?
|
| Deoxycytidine | 4 | 2020 | 35 | 1.370 |
Why?
|
| Nanomedicine | 6 | 2025 | 52 | 1.360 |
Why?
|
| Xenograft Model Antitumor Assays | 15 | 2020 | 339 | 1.330 |
Why?
|
| Blood Proteins | 4 | 2015 | 75 | 1.280 |
Why?
|
| Neoplasm Metastasis | 7 | 2024 | 233 | 1.270 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2020 | 134 | 1.180 |
Why?
|
| Mice, Nude | 15 | 2020 | 403 | 1.140 |
Why?
|
| beta-Cyclodextrins | 5 | 2016 | 35 | 1.100 |
Why?
|
| Polyglycolic Acid | 5 | 2016 | 48 | 1.100 |
Why?
|
| Apoptosis | 20 | 2022 | 1541 | 1.080 |
Why?
|
| Lactic Acid | 5 | 2016 | 110 | 1.050 |
Why?
|
| Stomach Neoplasms | 2 | 2024 | 228 | 1.000 |
Why?
|
| Mice | 31 | 2023 | 6490 | 1.000 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2023 | 933 | 0.990 |
Why?
|
| Nanotechnology | 4 | 2020 | 176 | 0.980 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2019 | 233 | 0.930 |
Why?
|
| Cell Movement | 12 | 2020 | 640 | 0.910 |
Why?
|
| Immunoconjugates | 1 | 2024 | 8 | 0.890 |
Why?
|
| Triterpenes | 3 | 2019 | 18 | 0.880 |
Why?
|
| Paclitaxel | 3 | 2019 | 64 | 0.880 |
Why?
|
| Signal Transduction | 17 | 2020 | 2111 | 0.870 |
Why?
|
| Antiviral Agents | 3 | 2022 | 189 | 0.860 |
Why?
|
| Ferric Compounds | 3 | 2019 | 62 | 0.830 |
Why?
|
| Nervous System Diseases | 2 | 2021 | 76 | 0.800 |
Why?
|
| Glycoproteins | 5 | 2014 | 127 | 0.800 |
Why?
|
| Antibodies, Monoclonal | 8 | 2011 | 301 | 0.780 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 502 | 0.780 |
Why?
|
| Esophageal Neoplasms | 1 | 2024 | 137 | 0.750 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 81 | 0.740 |
Why?
|
| Probiotics | 1 | 2022 | 37 | 0.740 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 86 | 0.740 |
Why?
|
| Carcinoma in Situ | 2 | 2019 | 16 | 0.720 |
Why?
|
| Female | 37 | 2025 | 24018 | 0.700 |
Why?
|
| Small Molecule Libraries | 3 | 2025 | 60 | 0.650 |
Why?
|
| Protein Interaction Mapping | 1 | 2020 | 64 | 0.640 |
Why?
|
| Benzimidazoles | 1 | 2019 | 41 | 0.630 |
Why?
|
| Nanostructures | 3 | 2022 | 158 | 0.620 |
Why?
|
| Tubulin | 2 | 2019 | 94 | 0.600 |
Why?
|
| Imidazoles | 1 | 2019 | 138 | 0.600 |
Why?
|
| Tubulin Modulators | 1 | 2019 | 18 | 0.600 |
Why?
|
| Neoplasm Invasiveness | 6 | 2020 | 284 | 0.590 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2018 | 6 | 0.590 |
Why?
|
| Pancreatic Cyst | 1 | 2018 | 6 | 0.590 |
Why?
|
| Erythrocytes | 3 | 2019 | 126 | 0.580 |
Why?
|
| Antigens, Neoplasm | 5 | 2007 | 77 | 0.580 |
Why?
|
| Tumor Stem Cell Assay | 6 | 2014 | 32 | 0.580 |
Why?
|
| Indoles | 1 | 2019 | 178 | 0.570 |
Why?
|
| Cell Nucleus | 6 | 2024 | 383 | 0.570 |
Why?
|
| Alphapapillomavirus | 2 | 2009 | 30 | 0.560 |
Why?
|
| Immunohistochemistry | 9 | 2019 | 928 | 0.550 |
Why?
|
| Papillomavirus E7 Proteins | 3 | 2019 | 16 | 0.550 |
Why?
|
| Endocytosis | 5 | 2019 | 117 | 0.530 |
Why?
|
| CA-125 Antigen | 2 | 2007 | 11 | 0.520 |
Why?
|
| Poloxamer | 1 | 2016 | 13 | 0.520 |
Why?
|
| Cell Survival | 8 | 2020 | 934 | 0.510 |
Why?
|
| Immunotherapy | 3 | 2023 | 137 | 0.500 |
Why?
|
| beta Catenin | 5 | 2017 | 75 | 0.500 |
Why?
|
| Protein Binding | 8 | 2020 | 1076 | 0.490 |
Why?
|
| Colon | 2 | 2016 | 118 | 0.480 |
Why?
|
| Protein Kinase C | 5 | 2019 | 124 | 0.460 |
Why?
|
| Chemical Phenomena | 1 | 2015 | 56 | 0.450 |
Why?
|
| Polyethyleneimine | 2 | 2011 | 9 | 0.440 |
Why?
|
| Tumor Cells, Cultured | 7 | 2020 | 506 | 0.440 |
Why?
|
| Receptors, Immunologic | 1 | 2014 | 70 | 0.430 |
Why?
|
| Magnetics | 2 | 2012 | 43 | 0.430 |
Why?
|
| Polyethylene Glycols | 2 | 2011 | 101 | 0.420 |
Why?
|
| Up-Regulation | 5 | 2018 | 534 | 0.410 |
Why?
|
| Smoking | 1 | 2020 | 1019 | 0.410 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 184 | 0.410 |
Why?
|
| Male | 28 | 2025 | 22779 | 0.400 |
Why?
|
| Repressor Proteins | 2 | 2018 | 267 | 0.400 |
Why?
|
| Chemistry, Pharmaceutical | 4 | 2015 | 93 | 0.400 |
Why?
|
| Prognosis | 5 | 2023 | 850 | 0.400 |
Why?
|
| Technology, Pharmaceutical | 1 | 2013 | 32 | 0.390 |
Why?
|
| Membrane Potential, Mitochondrial | 4 | 2019 | 89 | 0.390 |
Why?
|
| Drug Design | 2 | 2011 | 183 | 0.390 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 228 | 0.390 |
Why?
|
| Blotting, Western | 6 | 2014 | 884 | 0.390 |
Why?
|
| Cell Cycle | 4 | 2019 | 348 | 0.370 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 382 | 0.370 |
Why?
|
| Antibodies, Neoplasm | 5 | 2007 | 20 | 0.370 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 680 | 0.370 |
Why?
|
| Reactive Oxygen Species | 3 | 2023 | 518 | 0.360 |
Why?
|
| Cellulose | 1 | 2012 | 23 | 0.360 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2011 | 2 | 0.350 |
Why?
|
| Tannins | 3 | 2020 | 10 | 0.350 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2011 | 25 | 0.340 |
Why?
|
| Drug Compounding | 2 | 2017 | 90 | 0.340 |
Why?
|
| Particle Size | 5 | 2022 | 267 | 0.340 |
Why?
|
| Retinoblastoma Protein | 1 | 2011 | 29 | 0.340 |
Why?
|
| Breast Neoplasms | 4 | 2022 | 1679 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2025 | 159 | 0.340 |
Why?
|
| Xanthones | 2 | 2020 | 6 | 0.330 |
Why?
|
| Neoplasm Staging | 4 | 2018 | 366 | 0.330 |
Why?
|
| Liver Neoplasms | 2 | 2012 | 211 | 0.330 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 83 | 0.330 |
Why?
|
| Exosomes | 2 | 2022 | 124 | 0.320 |
Why?
|
| Benzo(a)pyrene | 1 | 2011 | 128 | 0.320 |
Why?
|
| Indians, North American | 3 | 2011 | 179 | 0.310 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 130 | 0.310 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 1554 | 0.310 |
Why?
|
| Liver | 1 | 2012 | 503 | 0.310 |
Why?
|
| Tissue Array Analysis | 3 | 2018 | 79 | 0.300 |
Why?
|
| Microscopy, Confocal | 4 | 2019 | 223 | 0.300 |
Why?
|
| Phosphorylation | 6 | 2020 | 973 | 0.290 |
Why?
|
| Gene Knockdown Techniques | 3 | 2020 | 188 | 0.290 |
Why?
|
| Prostate-Specific Antigen | 3 | 2016 | 145 | 0.280 |
Why?
|
| Macrophages | 2 | 2024 | 515 | 0.280 |
Why?
|
| Tumor Virus Infections | 1 | 2007 | 22 | 0.270 |
Why?
|
| Antibodies | 2 | 2007 | 140 | 0.270 |
Why?
|
| Cell Adhesion | 4 | 2020 | 237 | 0.270 |
Why?
|
| Hemolysis | 3 | 2019 | 59 | 0.270 |
Why?
|
| Carcinoma | 2 | 2006 | 106 | 0.260 |
Why?
|
| Materials Testing | 3 | 2019 | 99 | 0.260 |
Why?
|
| MAP Kinase Signaling System | 3 | 2025 | 189 | 0.260 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 438 | 0.260 |
Why?
|
| TRPP Cation Channels | 2 | 2018 | 5 | 0.250 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2006 | 20 | 0.250 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2006 | 24 | 0.250 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2006 | 19 | 0.250 |
Why?
|
| Down-Regulation | 5 | 2016 | 452 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 577 | 0.250 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 479 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2020 | 1112 | 0.250 |
Why?
|
| Immunoglobulin Fragments | 5 | 2005 | 12 | 0.240 |
Why?
|
| Cell Differentiation | 2 | 2020 | 633 | 0.240 |
Why?
|
| Intracellular Space | 2 | 2018 | 37 | 0.230 |
Why?
|
| Antimitotic Agents | 1 | 2025 | 2 | 0.230 |
Why?
|
| Oxidative Stress | 2 | 2023 | 990 | 0.230 |
Why?
|
| Cohort Studies | 2 | 2025 | 1729 | 0.230 |
Why?
|
| Neurofilament Proteins | 1 | 2025 | 30 | 0.230 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2025 | 24 | 0.230 |
Why?
|
| Human papillomavirus 16 | 2 | 2020 | 37 | 0.230 |
Why?
|
| Lutetium | 1 | 2004 | 3 | 0.230 |
Why?
|
| Taxoids | 2 | 2016 | 50 | 0.220 |
Why?
|
| Radioisotopes | 1 | 2004 | 17 | 0.220 |
Why?
|
| Aged | 7 | 2025 | 7982 | 0.220 |
Why?
|
| Coumarins | 1 | 2025 | 43 | 0.220 |
Why?
|
| Pyrroles | 1 | 2024 | 68 | 0.220 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 649 | 0.220 |
Why?
|
| Receptor, erbB-2 | 3 | 2011 | 149 | 0.210 |
Why?
|
| Inulin | 1 | 2024 | 2 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 55 | 0.210 |
Why?
|
| Mitosis | 1 | 2025 | 112 | 0.210 |
Why?
|
| Middle Aged | 9 | 2025 | 11819 | 0.210 |
Why?
|
| Pyrimidines | 1 | 2024 | 130 | 0.210 |
Why?
|
| Transfection | 3 | 2019 | 526 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 456 | 0.200 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2023 | 7 | 0.200 |
Why?
|
| Cervix Uteri | 4 | 2020 | 47 | 0.200 |
Why?
|
| Surgical Instruments | 1 | 2022 | 7 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 3 | 2018 | 454 | 0.200 |
Why?
|
| Ferrichrome | 1 | 2022 | 2 | 0.200 |
Why?
|
| Monitoring, Immunologic | 1 | 2022 | 3 | 0.200 |
Why?
|
| Siderophores | 1 | 2022 | 14 | 0.200 |
Why?
|
| Cisplatin | 2 | 2015 | 91 | 0.200 |
Why?
|
| Membrane Proteins | 1 | 2006 | 548 | 0.190 |
Why?
|
| Biological Availability | 2 | 2013 | 115 | 0.190 |
Why?
|
| Cell Adhesion Molecules | 1 | 2023 | 84 | 0.190 |
Why?
|
| Drug Synergism | 4 | 2020 | 189 | 0.190 |
Why?
|
| Structure-Activity Relationship | 2 | 2024 | 491 | 0.190 |
Why?
|
| Tissue Distribution | 5 | 2013 | 230 | 0.190 |
Why?
|
| Neurodegenerative Diseases | 1 | 2024 | 138 | 0.190 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2022 | 7 | 0.190 |
Why?
|
| Fertility | 1 | 2002 | 63 | 0.190 |
Why?
|
| Models, Molecular | 2 | 2019 | 875 | 0.190 |
Why?
|
| Ovary | 2 | 2016 | 112 | 0.180 |
Why?
|
| Mutation | 2 | 2024 | 1169 | 0.180 |
Why?
|
| Oligopeptides | 1 | 2002 | 108 | 0.180 |
Why?
|
| Lipid Metabolism | 2 | 2020 | 140 | 0.180 |
Why?
|
| Parkinson Disease | 1 | 2024 | 207 | 0.180 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 165 | 0.180 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2021 | 23 | 0.180 |
Why?
|
| Contraception | 1 | 2002 | 60 | 0.180 |
Why?
|
| Flow Cytometry | 2 | 2014 | 411 | 0.180 |
Why?
|
| Cell Membrane | 3 | 2019 | 400 | 0.180 |
Why?
|
| Vaccines | 1 | 2002 | 64 | 0.180 |
Why?
|
| Pancreas | 2 | 2016 | 45 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 209 | 0.180 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2020 | 19 | 0.170 |
Why?
|
| Cystic Fibrosis | 1 | 2020 | 27 | 0.170 |
Why?
|
| Receptors, Androgen | 2 | 2014 | 144 | 0.170 |
Why?
|
| Adult | 7 | 2025 | 13458 | 0.170 |
Why?
|
| p21-Activated Kinases | 2 | 2011 | 18 | 0.170 |
Why?
|
| Spermatozoa | 1 | 2002 | 208 | 0.170 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2020 | 6 | 0.170 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2020 | 5 | 0.170 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 2020 | 5 | 0.170 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2020 | 17 | 0.170 |
Why?
|
| Peptides | 2 | 2004 | 357 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2020 | 26 | 0.160 |
Why?
|
| Pancreatitis, Chronic | 1 | 2019 | 6 | 0.160 |
Why?
|
| src-Family Kinases | 1 | 2020 | 50 | 0.160 |
Why?
|
| Calcium | 1 | 2023 | 487 | 0.160 |
Why?
|
| Kinetics | 2 | 2020 | 698 | 0.160 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 33 | 0.160 |
Why?
|
| Clone Cells | 1 | 2019 | 50 | 0.160 |
Why?
|
| Serum | 1 | 2019 | 17 | 0.160 |
Why?
|
| Anemia, Hemolytic, Congenital | 1 | 2019 | 1 | 0.150 |
Why?
|
| Hydrops Fetalis | 1 | 2019 | 1 | 0.150 |
Why?
|
| Membrane Microdomains | 1 | 2019 | 53 | 0.150 |
Why?
|
| Chemokine CXCL12 | 1 | 2019 | 32 | 0.150 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 81 | 0.150 |
Why?
|
| Transplantation, Heterologous | 4 | 2019 | 98 | 0.150 |
Why?
|
| Dietary Supplements | 1 | 2020 | 208 | 0.150 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 97 | 0.150 |
Why?
|
| Biological Transport | 2 | 2016 | 201 | 0.150 |
Why?
|
| Mitochondria | 1 | 2023 | 516 | 0.150 |
Why?
|
| Ion Channels | 1 | 2019 | 74 | 0.150 |
Why?
|
| Ion Channel Gating | 1 | 2019 | 81 | 0.150 |
Why?
|
| Neoplasm Transplantation | 3 | 2018 | 129 | 0.150 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2020 | 183 | 0.150 |
Why?
|
| Microscopy, Atomic Force | 2 | 2019 | 62 | 0.150 |
Why?
|
| Transcription Factors | 1 | 2023 | 722 | 0.150 |
Why?
|
| Receptors, CXCR4 | 1 | 2019 | 74 | 0.150 |
Why?
|
| Hela Cells | 1 | 2019 | 370 | 0.150 |
Why?
|
| Mucin-1 | 3 | 2007 | 11 | 0.150 |
Why?
|
| Spectrum Analysis | 1 | 2018 | 59 | 0.140 |
Why?
|
| Dietary Fats | 1 | 2019 | 117 | 0.140 |
Why?
|
| Cytoplasm | 3 | 2018 | 154 | 0.140 |
Why?
|
| Mucin-4 | 6 | 2008 | 6 | 0.140 |
Why?
|
| Photons | 1 | 2018 | 29 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 236 | 0.140 |
Why?
|
| Drug Discovery | 3 | 2025 | 106 | 0.140 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 1066 | 0.140 |
Why?
|
| Computational Biology | 1 | 2020 | 324 | 0.140 |
Why?
|
| Appalachian Region | 1 | 2017 | 5 | 0.140 |
Why?
|
| I-kappa B Kinase | 1 | 2018 | 50 | 0.140 |
Why?
|
| Virus Replication | 1 | 2020 | 318 | 0.140 |
Why?
|
| Histone Deacetylases | 1 | 2018 | 61 | 0.140 |
Why?
|
| Gene Silencing | 1 | 2018 | 154 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2018 | 147 | 0.130 |
Why?
|
| Radioimmunotherapy | 3 | 2005 | 5 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2018 | 336 | 0.130 |
Why?
|
| Ammonia | 1 | 2016 | 22 | 0.130 |
Why?
|
| Oncogene Proteins | 2 | 2020 | 22 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2018 | 2485 | 0.130 |
Why?
|
| Gastric Mucosa | 1 | 2016 | 64 | 0.130 |
Why?
|
| Radiopharmaceuticals | 3 | 2005 | 62 | 0.130 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 196 | 0.130 |
Why?
|
| Epithelial Cells | 1 | 2020 | 426 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 972 | 0.120 |
Why?
|
| Dextrans | 1 | 2016 | 28 | 0.120 |
Why?
|
| Prostate | 2 | 2020 | 152 | 0.120 |
Why?
|
| Swine | 1 | 2016 | 205 | 0.120 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2016 | 184 | 0.120 |
Why?
|
| Ubiquitins | 1 | 2015 | 47 | 0.120 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2015 | 52 | 0.120 |
Why?
|
| Fluorouracil | 1 | 2015 | 46 | 0.120 |
Why?
|
| Hyperthermia, Induced | 2 | 2017 | 27 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2020 | 467 | 0.120 |
Why?
|
| Surface Properties | 2 | 2018 | 157 | 0.110 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2015 | 24 | 0.110 |
Why?
|
| Protective Agents | 1 | 2015 | 26 | 0.110 |
Why?
|
| Static Electricity | 1 | 2015 | 85 | 0.110 |
Why?
|
| Risk Factors | 2 | 2021 | 3942 | 0.110 |
Why?
|
| Adsorption | 1 | 2015 | 74 | 0.110 |
Why?
|
| TCF Transcription Factors | 1 | 2014 | 17 | 0.110 |
Why?
|
| RNA Interference | 2 | 2015 | 246 | 0.110 |
Why?
|
| RNA, Small Interfering | 3 | 2012 | 436 | 0.110 |
Why?
|
| In Situ Hybridization | 1 | 2014 | 134 | 0.110 |
Why?
|
| Cell Division | 2 | 2013 | 314 | 0.110 |
Why?
|
| Allyl Compounds | 1 | 2015 | 53 | 0.110 |
Why?
|
| Sulfides | 1 | 2015 | 77 | 0.110 |
Why?
|
| Incidence | 1 | 2017 | 1054 | 0.110 |
Why?
|
| HIV-1 | 1 | 2020 | 747 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2017 | 227 | 0.100 |
Why?
|
| Protein Engineering | 2 | 2005 | 47 | 0.100 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 25 | 0.100 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 106 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 61 | 0.100 |
Why?
|
| STAT5 Transcription Factor | 1 | 2013 | 48 | 0.100 |
Why?
|
| Protein Conformation | 1 | 2014 | 420 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2013 | 84 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 150 | 0.100 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2013 | 31 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2013 | 165 | 0.100 |
Why?
|
| Cell Aggregation | 2 | 2009 | 18 | 0.090 |
Why?
|
| S100 Proteins | 1 | 2011 | 13 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 160 | 0.090 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2011 | 103 | 0.090 |
Why?
|
| Serum Albumin | 1 | 2011 | 58 | 0.090 |
Why?
|
| Dendrimers | 1 | 2011 | 15 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 98 | 0.090 |
Why?
|
| Immunologic Factors | 2 | 2021 | 50 | 0.090 |
Why?
|
| Propylene Glycols | 1 | 2010 | 6 | 0.090 |
Why?
|
| Glycosylation | 1 | 2011 | 111 | 0.090 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2020 | 99 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 146 | 0.080 |
Why?
|
| Papillomaviridae | 1 | 2011 | 136 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 3 | 2005 | 30 | 0.080 |
Why?
|
| Thermogravimetry | 1 | 2010 | 7 | 0.080 |
Why?
|
| RNA | 1 | 2012 | 266 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2020 | 1586 | 0.080 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2010 | 36 | 0.080 |
Why?
|
| X-Ray Diffraction | 1 | 2010 | 66 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2011 | 574 | 0.080 |
Why?
|
| Vaccination | 2 | 2022 | 332 | 0.080 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2010 | 82 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 201 | 0.080 |
Why?
|
| Microscopy, Electron | 1 | 2010 | 209 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 221 | 0.080 |
Why?
|
| Xenobiotics | 2 | 2015 | 14 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 43 | 0.080 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2009 | 31 | 0.080 |
Why?
|
| Bryostatins | 1 | 2008 | 3 | 0.070 |
Why?
|
| United States | 2 | 2017 | 5072 | 0.070 |
Why?
|
| Genotype | 2 | 2011 | 796 | 0.070 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 599 | 0.070 |
Why?
|
| Iodine Radioisotopes | 2 | 2005 | 39 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2025 | 249 | 0.070 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 1188 | 0.070 |
Why?
|
| Actins | 1 | 2009 | 162 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1559 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2011 | 1265 | 0.070 |
Why?
|
| Human papillomavirus 18 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Midwestern United States | 1 | 2007 | 21 | 0.070 |
Why?
|
| Organ Specificity | 2 | 2005 | 141 | 0.070 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2007 | 71 | 0.070 |
Why?
|
| Vaginal Smears | 1 | 2007 | 62 | 0.070 |
Why?
|
| Host-Pathogen Interactions | 1 | 2009 | 203 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 236 | 0.070 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2007 | 57 | 0.060 |
Why?
|
| Prevalence | 2 | 2011 | 1597 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2006 | 69 | 0.060 |
Why?
|
| Antigens | 1 | 2006 | 58 | 0.060 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2002 | 39 | 0.060 |
Why?
|
| DNA, Viral | 1 | 2007 | 323 | 0.060 |
Why?
|
| Immunotoxins | 1 | 2005 | 13 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2006 | 362 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2006 | 268 | 0.060 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2005 | 22 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 214 | 0.060 |
Why?
|
| Adolescent | 4 | 2011 | 5950 | 0.060 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 29 | 0.060 |
Why?
|
| Angiotensin II | 1 | 2005 | 103 | 0.050 |
Why?
|
| Prebiotics | 1 | 2024 | 6 | 0.050 |
Why?
|
| Cryopreservation | 1 | 2024 | 33 | 0.050 |
Why?
|
| Indocyanine Green | 1 | 2023 | 4 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2005 | 318 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2015 | 98 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2022 | 59 | 0.050 |
Why?
|
| NADPH-Ferrihemoprotein Reductase | 1 | 2002 | 10 | 0.050 |
Why?
|
| Acrosome Reaction | 1 | 2002 | 3 | 0.050 |
Why?
|
| Sperm-Ovum Interactions | 1 | 2002 | 14 | 0.050 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2002 | 35 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2024 | 93 | 0.050 |
Why?
|
| Cholera Toxin | 1 | 2002 | 41 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2024 | 560 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2002 | 63 | 0.050 |
Why?
|
| RNA, Untranslated | 1 | 2022 | 46 | 0.050 |
Why?
|
| Biopsy | 1 | 2022 | 176 | 0.050 |
Why?
|
| Subcellular Fractions | 2 | 2014 | 79 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 117 | 0.050 |
Why?
|
| South Dakota | 2 | 2011 | 4 | 0.050 |
Why?
|
| Breast | 1 | 2022 | 139 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 239 | 0.040 |
Why?
|
| Polymers | 1 | 2022 | 151 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2022 | 94 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 253 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 26 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 522 | 0.040 |
Why?
|
| Resins, Plant | 1 | 2020 | 5 | 0.040 |
Why?
|
| Garcinia | 1 | 2020 | 5 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 14 | 0.040 |
Why?
|
| Drug Costs | 1 | 2020 | 36 | 0.040 |
Why?
|
| U937 Cells | 1 | 2020 | 30 | 0.040 |
Why?
|
| Culture Media | 1 | 2020 | 96 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2020 | 118 | 0.040 |
Why?
|
| Cell Line | 1 | 2023 | 1416 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2019 | 36 | 0.040 |
Why?
|
| Urban Population | 2 | 2011 | 364 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 1 | 2019 | 228 | 0.040 |
Why?
|
| Rural Population | 2 | 2011 | 352 | 0.040 |
Why?
|
| Biosensing Techniques | 1 | 2020 | 130 | 0.040 |
Why?
|
| Glucose | 1 | 2019 | 242 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2019 | 134 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2018 | 54 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 59 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 733 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 661 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 173 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 167 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 2803 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2018 | 190 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 711 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 683 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 230 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2008 | 293 | 0.030 |
Why?
|
| Cytosol | 1 | 2016 | 98 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2015 | 29 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2015 | 36 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2014 | 60 | 0.030 |
Why?
|
| Analgesics | 1 | 2015 | 55 | 0.030 |
Why?
|
| DNA Primers | 2 | 2005 | 295 | 0.030 |
Why?
|
| Binding Sites | 1 | 2015 | 670 | 0.030 |
Why?
|
| Cofilin 1 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Ethanol | 1 | 2015 | 221 | 0.020 |
Why?
|
| Time Factors | 2 | 2008 | 1848 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 602 | 0.020 |
Why?
|
| Biotinylation | 1 | 2011 | 12 | 0.020 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2011 | 25 | 0.020 |
Why?
|
| Symporters | 1 | 2011 | 15 | 0.020 |
Why?
|
| Young Adult | 2 | 2011 | 4936 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 277 | 0.020 |
Why?
|
| trans-Golgi Network | 1 | 2008 | 5 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 2008 | 47 | 0.020 |
Why?
|
| Cadherins | 1 | 2008 | 102 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 173 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 1139 | 0.020 |
Why?
|
| Protein Transport | 1 | 2008 | 295 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 462 | 0.020 |
Why?
|
| Interleukins | 1 | 2006 | 37 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 25 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2011 | 634 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2005 | 26 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 534 | 0.010 |
Why?
|
| Gene Products, tat | 1 | 2005 | 36 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 1737 | 0.010 |
Why?
|
| Surface Plasmon Resonance | 1 | 2005 | 35 | 0.010 |
Why?
|
| Dimerization | 1 | 2005 | 115 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 198 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2005 | 165 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2004 | 10 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2004 | 76 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 427 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2004 | 158 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2006 | 274 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2006 | 1266 | 0.010 |
Why?
|
| Islets of Langerhans | 1 | 2002 | 13 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 458 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 318 | 0.010 |
Why?
|
| Infant | 1 | 2002 | 1143 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 1617 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2002 | 1516 | 0.010 |
Why?
|
| Rats | 1 | 2002 | 3701 | 0.010 |
Why?
|
| Child | 1 | 2002 | 3381 | 0.010 |
Why?
|